Vera Therapeutics Reports Positive Phase 3 Trial Results for Trutakna in IgA Nephropathy

Vera Therapeutics Inc. announced its drug candidate, trutakna, met all primary efficacy endpoints in the final analysis of the ORIGIN 3 Phase 3 trial for primary IgA nephropathy (IgAN). This marks a significant step toward potential FDA approval for treating this serious, progressive kidney disorder. Trutakna, an inhibitor targeting BAFF and APRIL pathways, demonstrated statistically significant improvements in kidney function (eGFR) and reduced proteinuria, with a safety profile comparable to placebo.